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with extensive sex-cord pattern with positive surgical margins.
Fewweeks later the patient had subsequent complete staging includ-
ing bilateral salpingo-oophorectomy, omentectomy, parametrectomy,
pelvic lymphadenectomy and uterine cervical resection. A central pathol-
ogy review revealed a 12.0 cm sex-cord uterine tumor resembling an
ovarian sex-cord tumor with Sertoli cell-like differentiation. The neopla-
sia was characterized by epithelioid polygonal or cylindrical cells in solid
cordonal architecture or anastomosing trabecule disposed in a dense
colagenic stroma. No stromal endometrioid areas were identiﬁed. The
tumor had ﬁngerlike projections and endovascular growth, withmultifo-
cal myometrial vascular embolization and inﬁltration of the entire
myometrial layer up to the serosal layer (Fig. 1). Pathology analysis also
revealed that the tumor extended to uterine cervix, right parametrium1. Introduction
involved.
Immunohistochemistry study (IHC) revealed strong positivity forUterine tumors with sex-cord elements are very rare. Clement and
Scully described 14 patients in 1976 (Clement and Scully, 1976). The
authors divided these tumors into two groups: one corresponding to
endometrial stromal neoplasms with focal areas resembling ovarian
sex-cord elements (also called endometrial stromal tumors with sex
cord-like elements— ESTSCLE) and the other corresponding to intramu-
ral uterine tumors with a predominant or exclusive pattern similar to
ovarian sex-cord tumor (also called uterine tumors resembling ovarian
sex-cord tumor — UTROSCT) (Clement and Scully, 1976; Czernobilsky,
2008). We describe a patient diagnosed with locally advanced
UTROSCT with an unusual pattern of inﬁltration and growth, similar to
endometrial stromal sarcomas.2. Case report
This is a 53-year-old female, heavy smoker,whohad a history of irreg-
ular vaginal bleeding for the past two years, which led to a supracervical, n° 951, Bela Vista, CEP: 01321-
lomena@usp.br (F.M. Carvalho),
.C. Maluf).
en access article under the CC BY-NCand right ovarium hilum. There were extense ischemic areas. The right
parametrial surgical margin was positive. Pelvic lymph nodes were not
vimentin, CD99, cytokeratins AE1/AE3, estrogen and progesterone re-
ceptors and focal positivity forWT-1.Weak immunoreactivitywas pres-
ent for CD10, melan-A, inhibin and desmin. IHC was negative for alpha-
smooth muscle actin, muscle actin (HHF35) and epithelial membrane
antigen (EMA).
Computed tomography of thorax, abdomen and pelvis revealed no
evidence of metastatic disease. She was treated with 4 cycles of adju-
vant modiﬁed BEP every 3 weeks (bleomycin 20 U/m2 (intravenous)
IV on day 1, cisplatin 20 mg/m2 IV from days 1 to 5, and etoposide
100 mg/m2 IV from days 1 to 5), followed by external pelvic radiation
at the total dose of 45 Gy over 5 weeks and brachytherapy (dose of
6 Gy in 4 fractions). There were no grade III or IV toxicities during the
entire treatment. After a 5-year follow-up, there was no evidence of
disease.3. Discussion
Uterine sex-cord tumors occur most frequently between the fourth
and the sixth decades of life (Kunz and Friedrich, 2007; Garuti et al.,
2009). Both UTROSCT and ESTSCLE correspond to uterine tumors with
sex cord-like elements although they may represent distinct entities
(Pradhan and Mohanty, 2013). Histologically, UTROSCT consists pre-
dominantly or exclusively by similar ovarian sex-cord tumor elements-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Uterine tumor sections showing trabeculae and anastomosing cords of epithelioid cells (A) with areas of sertoliform (B) and retiform structures (C). Endovascular growth was
evident (D) (hematoxylin–eosin).
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architectural patterns seen in either granulosa or Sertoli–Leydig ovarian
tumors (Czernobilsky, 2008; Pradhan andMohanty, 2013). On the other
hand, ESTSCLE is characterized by sex-cord elements in less than 50% of
the tumor area and in lesser degree compared to UTROSCT (Clement
and Scully, 1976; Pradhan and Mohanty, 2013).
IHC has been a useful tool in sex-cord differentiation, particularly
calretinin, inhibin, CD99, and melan-A (Czernobilsky, 2008; Irving et al.,
2006). Some tumors may also have expression of epithelial and smooth
muscle markers demonstrating the polyphenotypic proﬁle of these
tumors (Czernobilsky, 2008).
Although UTROSCT has been viewed as a variant of endometrial
stromal sarcoma, it seems that only ESTSCLE can be considered a truly
variant. The t(7;17)(p15;q21) translocation resulting in the fusion
gene JAZF1–JJAZ1 that characterizes the endometrial sarcomas is not
observed in UTROSCT (Staats et al., 2009).
The correct diagnosis is key to guide optimal management. The
prognosis of ESTSCLE is that of endometrial stromal sarcomas, charac-
terized by loco-regional and distant relapses (Czernobilsky, 2008). On
the other hand, UTROSCT is considered to be of lowmalignant potential
tumor andmost are described as benign (Czernobilsky, 2008; Kunz and
Friedrich, 2007; Pradhan and Mohanty, 2013). However, UTROSCT bio-
logic behavior remains to be established, particularly in cases like ours,
associated with inﬁltrative borders, endovascular invasion and
extrauterine extension.
Therapy has been based on case reports and data relying on ovarian
sex-cord tumor. Surgerywith negativemargins has been considered the
backbone treatment of UTROSCT. Most case reports describe women
who underwent hysterectomy with or without bilateral salpingo-
oophorectomy as the initial approach. Pelvic lymphadenectomy,
omentectomy, parametrectomy, or even uterine cervical resection are
rarely described and should be individualized (Franco et al., 2003).
Some authors, however, propose conservative surgery as a standard
approach (Garuti et al., 2009; Hillard et al., 2004).
The role of adjuvant therapy in UTROSCT is uncertain. One case
report described a patient treated with adjuvant pelvic external beam
radiotherapy and brachytherapy with no evidence of recurrence at last
follow-up (Irving et al., 2006).Despite the fact that UTROSCT has a favorable biologic behavior, loco-
regional relapse may occur especially when simple hysterectomy has
been performed. Those patients are submitted to salvage surgery and
postoperative external beam radiotherapy (Clement and Scully, 1976;
Blinman and Tattersall, 2009; Malfetano and Hussain, 1989). Some
case reports describe distant recurrence fewyears after initial therapy.
Generally the sites of metastasis are intra-abdominal and include
small bowel, omentum, mesentery, and peritoneum. Subcutaneous
tissue, lymph nodes, and bladder involvement are also reported
(Malfetano and Hussain, 1989; O'Meara et al., 2009; Biermann et al.,
2008). Despite the heterogeneity, salvage treatment included mainly
resection of metastatic disease. Some patients had also been treated
with postoperative chemotherapy (BEP) or hormonal therapy (ta-
moxifen followed by anastrozole) (Malfetano and Hussain, 1989;
O'Meara et al., 2009; Biermann et al., 2008). Of interest, all patients
described had no evidence of disease at the last follow-up.
Our patient underwent radical surgery after an incomplete initial
surgical procedure followed by 4 cycles of adjuvantmodiﬁed BEP, pelvic
external beam radiation and brachytherapy due to positive surgical
margins and extra-uterine extension. The decision to recommend
chemotherapy with BEP was based on ovarian Sertoli–Leydig cell
tumors. Adjuvant systemic therapy has been considered in early
stage disease with adverse features or in non-organ conﬁned disease
(Colombo et al., 2007). Besides, BEP is an active combination regimen
for ﬁrst-line chemotherapy of malignant sex-cord tumors of the ovary
(Homesley et al., 1999). Similarly, radiation therapy seems to be effec-
tive in sex-cord tumors (Colombo et al., 2007). After a follow-up period
of 5 years, the patient has no evidence of recurrence.
4. Conclusion
The case report describes a patient with UTROSCT, an uncommon
tumor with variable biologic behavior, treated with radical surgery
after an incomplete initial surgical procedure, followed by adjuvant
modiﬁed BEP and pelvic external beam radiotherapy and brachytherapy,
24 J.R. Gomes et al. / Gynecologic Oncology Reports 15 (2016) 22–24with complete remission for a period of ﬁve years. As UTROSCT are rare
tumors, there are no prospective studies to delineate the optimal man-
agement. Therefore, aside from surgery with the goal of obtaining nega-
tivemargins, the extension of surgery as well as the decision of adjuvant
therapy must be individualized based on the extension of disease and
pathologic features.
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